Literature DB >> 19223641

Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.

Simon D Baines1, Jane Freeman, Mark H Wilcox.   

Abstract

The efficacy of tolevamer, a nonantimicrobial styrene derivative toxin-binding agent, in treating simulated Clostridium difficile infection in an in vitro human gut model was investigated. Tolevamer reduced neither the duration nor magnitude of cytotoxin activity by C. difficile, reflecting poor efficacy observed in recent phase III clinical trials.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19223641      PMCID： PMC2681510          DOI： 10.1128/AAC.01085-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients.

Authors:  L V McFarland; G W Elmer; W E Stamm; M E Mulligan
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

2.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

3.  Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.

Authors:  Simon D Baines; Jane Freeman; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2005-04-28       Impact factor: 5.790

4.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Authors:  Daniel M Musher; Saima Aslam; Nancy Logan; Srikanth Nallacheru; Imran Bhaila; Franziska Borchert; Richard J Hamill
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

5.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

6.  Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

Authors:  Simon D Baines; Katie Saxton; Jane Freeman; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2006-10-08       Impact factor: 5.790

Review 7.  Treatment of Clostridium difficile infection.

Authors:  Dale N Gerding; Carlene A Muto; Robert C Owens
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Michelle M Nerandzic; Greg S Bobulsky; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

9.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

10.  Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.

Authors:  Paul L Hinkson; Carol Dinardo; Daniel DeCiero; Jeffrey D Klinger; Robert H Barker
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191
View more
  12 in total

1.  Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

Review 2.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

Review 3.  Models for the study of Clostridium difficile infection.

Authors:  Emma L Best; Jane Freeman; Mark H Wilcox
Journal:  Gut Microbes       Date:  2012-03-01

Review 4.  Clostridium difficile infection.

Authors:  Latisha Heinlen; Jimmy D Ballard
Journal:  Am J Med Sci       Date:  2010-09       Impact factor: 2.378

Review 5.  Clostridium difficile and the microbiota.

Authors:  Anna M Seekatz; Vincent B Young
Journal:  J Clin Invest       Date:  2014-07-18       Impact factor: 14.808

Review 6.  The host immune response to Clostridium difficile infection.

Authors:  Katie Solomon
Journal:  Ther Adv Infect Dis       Date:  2013-02

7.  Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity.

Authors:  Ilana L Stroke; Jeffrey J Letourneau; Teresa E Miller; Yan Xu; Igor Pechik; Diana R Savoly; Linh Ma; Laurie J Sturzenbecker; Joan Sabalski; Philip D Stein; Maria L Webb; David W Hilbert
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  Trehalose-Induced Remodelling of the Human Microbiota Affects Clostridioides difficile Infection Outcome in an In Vitro Colonic Model: A Pilot Study.

Authors:  Anthony M Buckley; Ines B Moura; Norie Arai; William Spittal; Emma Clark; Yoshihiro Nishida; Hannah C Harris; Karen Bentley; Georgina Davis; Dapeng Wang; Suparna Mitra; Takanobu Higashiyama; Mark H Wilcox
Journal:  Front Cell Infect Microbiol       Date:  2021-07-02       Impact factor: 5.293

Review 9.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

10.  SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.

Authors:  S D Baines; G S Crowther; J Freeman; S Todhunter; R Vickers; M H Wilcox
Journal:  J Antimicrob Chemother       Date:  2014-09-03       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.